Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results.

World J Urol · 2020 · PMC7716857 · PMID 32088746

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

(3) Incidence of 18-month Gleason grade increase was significantly less in the FT 15-mg group compared to AS in the prostate overall (− 78.6%, p = 0.0102) and in the treated prostate lobe (− 73.6%, p = 0.0466), whereas the reductions in the 2.5-mg group did not reach statistical significance (− 59.5%, NS and − 64.6%, NS, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.